{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:34:02Z","timestamp":1793928842969,"version":"4.8.0"},"reference-count":6,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:p>\n                    This follow-up analysis of the phase 2 HERIZON-BTC-01 trial evaluates the efficacy, patient-reported outcomes, and safety profile of zanidatamab in patients with\n                    <jats:italic toggle=\"yes\">ERBB2<\/jats:italic>\n                    -amplified biliary tract cancer with a HER2 immunohistochemistry score of 3+ or 2+ after 33 months of follow-up.\n                  <\/jats:p>","DOI":"10.1001\/jamaoncol.2025.4736","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T16:00:36Z","timestamp":1763654436000},"page":"106","source":"Crossref","is-referenced-by-count":19,"title":["Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer"],"prefix":"10.1001","volume":"12","author":[{"given":"Shubham","family":"Pant","sequence":"first","affiliation":[{"name":"MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Fan","sequence":"additional","affiliation":[{"name":"Zhongshan Hospital of Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do-Youn","family":"Oh","sequence":"additional","affiliation":[{"name":"Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Jin","family":"Choi","sequence":"additional","affiliation":[{"name":"Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Won","family":"Kim","sequence":"additional","affiliation":[{"name":"Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heung-Moon","family":"Chang","sequence":"additional","affiliation":[{"name":"Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lequn","family":"Bao","sequence":"additional","affiliation":[{"name":"Hubei Cancer Hospital, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Chuan","family":"Sun","sequence":"additional","affiliation":[{"name":"Zhongshan Hospital of Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Macarulla","sequence":"additional","affiliation":[{"name":"Vall d\u2019Hebr\u00f3n University Hospital, Vall d\u2019Hebr\u00f3n Institute of Oncology, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xie","sequence":"additional","affiliation":[{"name":"The Third Affiliated Hospital of the Chinese People\u2019s Liberation Army Naval Military Medical University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Phillippe","family":"Metges","sequence":"additional","affiliation":[{"name":"CHRU de Brest - H\u00f4pital Morvan, ARPEGO Network, Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie\u2019er","family":"Ying","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Bridgewater","sequence":"additional","affiliation":[{"name":"University College London Cancer Institute, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Ah","family":"Lee","sequence":"additional","affiliation":[{"name":"The Catholic University of Korea, Seoul St. Mary\u2019s Hospital, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamedtaki A.","family":"Tejani","sequence":"additional","affiliation":[{"name":"AdventHealth, Altamonte Springs, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emerson Y.","family":"Chen","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpreet","family":"Wasan","sequence":"additional","affiliation":[{"name":"Hammersmith Hospital, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ducreux","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Saclay, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Bao","sequence":"additional","affiliation":[{"name":"BeOne Medicines, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotian","family":"Wu","sequence":"additional","affiliation":[{"name":"Jazz Pharmaceuticals, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[{"name":"BeOne Medicines, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip M.","family":"Garfin","sequence":"additional","affiliation":[{"name":"Jazz Pharmaceuticals, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon","family":"Gable","sequence":"additional","affiliation":[{"name":"Jazz Pharmaceuticals, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Harding","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"HERIZON-BTC-01 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghassan K","family":"Abou-Alfa","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Adeva","family":"Alfonso","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Aglietta","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Baron","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Beg","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula Carrasco","family":"Aguirre","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Chen","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cheng","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Cubillo","family":"Graci\u00e1n","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Dahan","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"De Braud","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Fenocchio","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olumide","family":"Gbolohon","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roopinder","family":"Gillmore","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Jary","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milind","family":"Javle","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixing","family":"Jiang","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Hun","family":"Kang","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gentry George","family":"King","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madappa","family":"Kundranda","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Layos","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daneng","family":"Li","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingbo","family":"Liang","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omkar","family":"Marathe","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Mondaca","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s J. Mu\u00f1oz","family":"Martin","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Oh","family":"Park","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Pazo Cid","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula Ribera","family":"Fernandez","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Rimassa","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Rodriguez","family":"Alonso","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Sadeghi","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Scott","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Tan","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tougeron","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Yan","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Yin","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Zhao","sequence":"additional","affiliation":[{"name":"for the HERIZON-BTC-01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"cld250024r1","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.","author":"Oh","journal-title":"NEJM Evid"},{"issue":"5","key":"cld250024r2","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1001\/jamaoncol.2023.0016","article-title":"Treatment with liposomal irinotecan plus fluorouracil and leucovorin for patients with previously treated metastatic biliary tract cancer: the phase 2b NIFTY randomized clinical trial.","volume":"9","author":"Hyung","year":"2023","journal-title":"JAMA Oncol"},{"issue":"1","key":"cld250024r3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10555-016-9645-x","article-title":"HER2\/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?","volume":"36","author":"Galdy","year":"2017","journal-title":"Cancer Metastasis Rev"},{"issue":"7","key":"cld250024r4","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"cld250024r6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial.","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"cld250024r5","unstructured":"Jazz Pharmaceuticals. Jazz Pharmaceuticals receives European Commission marketing authorization for Ziihera (zanidatamab) for the treatment of advanced HER2-positive biliary tract cancer. Accessed July 9, 2025. https:\/\/investor.jazzpharma.com\/node\/21951\/pdf"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2841674\/jamaoncology_pant_2025_ld_250024_1767385919.98958.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T16:01:16Z","timestamp":1768492876000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2841674"}},"subtitle":["Final Results From HERIZON-BTC-01"],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":6,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2025.4736","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,1]]}}}